NCT03140137View on ClinicalTrials.gov

Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases

CompletedOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

January 21, 2017

Primary Completion Date

January 4, 2018

Study Completion Date

January 4, 2018

Conditions
Autoimmune DiseasesAdvanced Cancer
Interventions
DRUG

Checkpoint inhibitor therapy

Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice

Trial Locations (5)

13616

CH d'AIX, Aix-en-Provence

21079

CHU de DIJON, Dijon

72000

Ch Le Mans, Le Mans

78018

CH de MACON, Mâcon

85925

CHD Vendée, La Roche-sur-Yon

All Listed Sponsors
lead

University Hospital, Brest

OTHER

NCT03140137 - Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases | Biotech Hunter | Biotech Hunter